Pfizer and Valneva’s Lyme disease vaccine candidate PF-07307405 reached a regulatory milestone as the EMA validated their Marketing Authorization Application (MAA). The submission concerns a 6-valent OspA-based vaccine, advancing the path toward potential approval in Europe.
Pfizer and Valneva’s Lyme disease vaccine candidate PF-07307405 reached a regulatory milestone as the EMA validated their Marketing Authorization Application (MAA). The submission concerns a 6-valent OspA-based vaccine, advancing the path toward potential approval in Europe.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
